INNOVATION IN SPORTS MEDICINE

Copeland Biosciences Corp. provides safe and effective remedies to relieve inflammatory pain with propriety formulations in conjunction with modern technology and innovative methods. Copeland Biosciences Corp's. proprietary formulations are delivered by an assortment of leading and cutting edge technologies ranging from Focal Acoustic Wave Therapy to Class IV Laser Therapy to wearable devices that include sound-wave technology, light energy, transdermal and heating agents. This Canadian based company unites the extensive orthopaedic knowledge of renowned podiatrist Glenn Copeland, who has over forty years of treating sports medicine injuries.

By employing medical protocols that have been developed through extensive consultation and testing, Copeland Biosciences has discovered the optimal methods for topically applying its extensive range of formulations. These ground-breaking discoveries utilize topical medicine concentrations, including CBD based remedies.

Copeland Biosciences is currently one of the very few medical companies studying and researching the topical applications of CBD oil as it relates to musculoskeletal injuries.

The company began its roll out on 17 October 2018, to coincide with the nationwide legalization of marijuana across Canada.

ABOUT US

Current options to treat problems such as osteoarthritis include:

NSAIDs

CORTICOSTEROIDS

HYALURONIC INJECTIONS

VISCOSUPPLEMENTATION

PHYSICAL THERAPY

JOINT REPLACEMENT

These solutions can lead to the following complications:

KIDNEY COMPLICATIONS

OSTEOPOROSIS

WEIGHT GAIN

HIGH BLOOD PRESSURE

BLEEDING IN THE INTESTINES AND STOMACH

ULCERS (IN UP TO 25% OF PATIENTS)1

ADDICTIVE AND PRONE TO ABUSE

As many as 19% of frequent NSAID users develop ulcers. The US FDA also released a warning that prolonged use of NSAIDs, other than aspirin, can increase the risk of heart attack and stroke.

One study conducted in Denmark 1996-2016 demonstrated that the NSAID Diclofenac posed significant cardiovascular risks.

The adverse incident rate for consumers of this drug was 50% higher than before they took it; far higher than those who took alternative medication or nothing at all.

COPELAND BIOSCIENCES’ SOLUTION

Dr Glenn Copeland has developed an innovative solution to these problems over the last three and a half years.

These formulations contain different concentrations of CBD oil; the quantities have been carefully tested to ensure efficacy.

Ground-breaking agents in the formulations will allow the cream to break through the epidermis and dermis and effectively treat the inflammation and injured tissue.

25% CBD

Concentrations of 25% CBD, on the other hand, are much better for treating ankle sprains

2%
CBD

2% concentration of CBD oil, for example, is perfect for treating joint inflammation.

114

The number of formulations Copeland Biosciences has developed targeting specific areas of tissue injury

All of these are topical formulations, allowing the user to apply the cream directly and solely to the affected area – avoiding the risk to the entire body posed by other forms of medication.

At present, Copeland Biosciences also holds the Canadian exclusive distributor rights to sam® Pro 2.0; an energy-wave based therapy which is safe and effective for reducing inflammation.

TARGET INDICATIONS

MUSCULAR AND TENDON INJURIES

Widespread osteoarthritis has created a huge potential market for treatment:

IN 2017,

THE MARKET WAS VALUED AT

$10.4

BILLION CAD

THE US CENTERS FOR DISEASE CONTROL (CDC) AND THE WORLD HEALTH ORGANIZATION (WHO) ESTIMATE THAT

30 MILLION

AMERICAN ADULTS AND

40 MILLION

EUROPEAN ADULTS ARE AFFECTED BY OSTEOARTHRITIS.3

IT IS EXPECTED TO REACH

$15.3

BILLION CAD

BY 2025 WITH A PREDICTED GROWTH RATE OF 4.8%.2

Tendonitis/ Overuse Injuries

The global tendinitis treatment market is expected to reach $461 Million CAD by the end of 2018 and is estimated to exceed more than $561 Million CAD by 2023 at a CAGR of 3.8%.4

  • Tendonitis (also spelt tendinitis) is the swelling of a tendon after an injury

  • This is the case in running, in which 40 million Americans partake regularly.6

50%

Approximately half of all sports injuries are a result of overuse6

  • According to the US Bureau of Labor Statistics, 70,000 people in the US miss work each year due to tendonitis.7

demo-clip-heptagon
demo-clip-heptagon
demo-clip-heptagon

Soft Tissue Inflammation

The global market is estimated to reach $5.12 Billion CAD by the end of 2018 and is projected to be worth $11.56 Billion CAD by 2025 at a CAGR of 8.3%.8

  • Soft tissue injuries include damage to any of the body’s muscles, tendons and ligaments.

  • Soft tissue covers a wide area of common injuries including sprained ankles – a problem 25,000 people suffer every day in the US. 9

10%

It also includes plantar fasciitis, a problem that 10% of the US population suffers from every year 10

Athletic Traumatic Injury

The global market was worth $7.6 Billion CAD in 2017 and is projected to rise to $10.84 Billion CAD by 2022 at a CAGR of 7.4%.11

  • Athletic traumatic injuries cover any problems that occur as a result of participation in sport.

  • In 2016/17, 17,655 Canadians were hospitalised due to sports injuries.12

Professional leagues pay dearly for injured players’ salaries in 2018:

Total amount paid for injured players’ salaries by professional leagues

All Units in $ CAD

APPLYING NEW DISCOVERIES TO SPORTS MEDICINE

Cutting-edge research being undertaken at the University of Oxford offers huge potential to the sports medicine market.

PROFESSOR

SIR MARC FELDMANN

Professor Sir Marc Feldmann’s work in combatting auto-immune diseases and inflammation over four decades is very applicable to Copeland Biosciences’ eventual aim of combatting the root causes of inflammation.

His experience can be applied to the new area of sports medicine, which remains relatively unexplored at the cutting-edge of science, and be used to improve the efficacy of Copeland Biosciences’ products.

PROFESSOR

JAGDEEP NANCHAHAL

Professor Nanchahal has recently led research into stem cells and the endogenous nuclear protein HMGB1.

This research is useful in one particularly exciting sense for Copeland Biosciences: HMGB1 accelerates the healing process in damaged tissue. Whilst Copeland Biosciences’ existing products are effective at dealing with inflammation, Nanchahal’s research would allow the company to explore healing tissue damage on a more substantive level.

Team

contact

COPELAND BIOSCIENCES CORP
99 Scollard Street,
Toronto, ON.
M5R 1G4,
CANADA